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Objectives: Cancer affects up to 20% of critically ill patients, and 
sepsis is one of the leading reasons for ICU admission in this set-
ting. Early signals suggested that survival might be increasing in 
this population. However, confirmation studies have been lacking. 
The goal of this study was to assess trends in survival rates over 
time in cancer patients admitted to the ICU for sepsis or septic 
shock over the last 2 decades.
Data Source: Seven European ICUs.
Study Selection: A hierarchical model taking into account the year 
of admission and the source dataset as random variables was 
used to identify risk factors for day 30 mortality.
Data Extraction: Data from cancer patients admitted to ICUs 
for sepsis or septic shock were extracted from the Groupe de 
Recherche Respiratoire en Réanimation Onco-Hématologique 
database (1994–2015).
Data Synthesis: Overall, 2,062 patients (62% men, median [in-
terquartile range] age 59 yr [48–67 yr]) were included in the 
study. Underlying malignancies were solid tumors (n = 362; 
17.6%) or hematologic malignancies (n = 1,700; 82.4%), including 
acute leukemia (n = 591; 28.7%), non-Hodgkin lymphoma (n = 461; 
22.3%), and myeloma (n = 244; 11.8%). Two-hundred fifty patients 
(12%) underwent allogeneic hematopoietic stem cell transplanta-
tion and 640 (31.0%) were neutropenic at ICU admission. Day 30 
mortality was 39.9% (823 deaths). The year of ICU admission was 
associated with significant decrease in day 30 mortality over time 
(odds ratio, 0.96; 95% CI, 0.93–0.98; p = 0.001). Mechanical ven-
tilation (odds ratio, 3.25; 95% CI, 2.52–4.19; p < 0.01) and vaso-
pressors use (odds ratio, 1.42; 95% CI, 1.10–1.83; p < 0.01) were 
independently associated with day 30 mortality, whereas underlying 
malignancy, allogeneic hematopoietic stem cell transplantation, and 
neutropenia were not.
Conclusions: Survival in critically ill oncology and hematology 
patients with sepsis improved significantly over time. As outcomes 
improve, clinicians should consider updating admission policies and 
goals of care in this population. (Crit Care Med 2020; XX:00–00)
Key Words: acute kidney injury; hematology; neutropenia; 
oncology; outcomes; stem cell transplantation
Major advances have been reported in diagnostic and management strategies of patients with malignan-cies, resulting in survival improvements over the past 
2 decades (1, 2). Furthermore, advances in cancer therapies, 
improvements in ICUs processes, and admission policies have 
contributed to improving overall survival (3–5). Consequently, 
the proportion of patients with malignancies admitted to the 
ICU has increased. Indeed, 5% of patients with solid tumors 
and up to 15% of patients with hematologic malignancies re-
quire ICU admissions due to life threatening conditions at the 
onset of the malignancy (6, 7). Furthermore, patients with 
malignancies account for approximately 20% of ICU admis-
sions nowadays (5, 8), and sepsis is one of the leading reasons 
for ICU admission in this setting (9, 10). The prevalence of 
sepsis in patients with cancer is higher than in the noncancer 
population (8). Indeed, the immunosuppression caused by the DOI: 10.1097/CCM.0000000000004322
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underlying disease and owing to treatments increase their risk 
for severe infections. In comparison to general patients with 
sepsis, patients with malignancies are at high risk of intractable 
multiple organ failures, experience prolonged lengths of stay, 
and higher morbidity and mortality (11, 12). Furthermore, in 
this population, other clinical or biological factors such as al-
logeneic bone marrow transplantation are known to be risk 
factors for mortality (13, 14). However, updated data in this 
setting are lacking. Studies to appraise outcomes in critically ill 
cancer patients with sepsis are warranted. In the present study, 
we sought to assess trends in survival rates over time in cancer 
patients admitted to the ICU for sepsis or septic shock
PATIENTS AND METHODS
Patients and Data
The Groupe de Recherche Respiratoire en Réanimation Onco-
Hématologique (GRRR-OH) database comprises data from all 
cancer patients admitted in the seven participating ICUs and 
included in one of the 14 prospective or retrospective pub-
lished studies of the research group, from 1994 to 2015. Data on 
cancer patients admitted in ICU for sepsis or septic shock were 
extracted from this database (3, 15–27). Appropriate institu-
tional review board approved each study (3, 15–27). Sepsis and 
septic shock were defined according to the third international 
sepsis definitions conference (28). All studies included the data 
points reported in tables and figures. Multiple organ failure was 
defined as the association of three organ dysfunctions defined 
by their organ support (vasopressors, mechanical ventilation, 
and renal replacement therapy). Neutropenia at ICU admission 
was defined as grade 4 neutropenia with a neutrophils count less 
than 500/mm3. Comorbidities included as follows: peripheral 
vascular disease, cirrhosis, chronic kidney disease, diabetes mel-
litus, congestive heart failure, chronic obstructive pulmonary 
disease, and dementia. The Sequential Organ Failure Assess-
ment (SOFA) score was computed at admission as previously 
defined (29); this score provides an estimate of the risk of death 
based on organ dysfunctions (3, 30, 31) (Supplemental Table 1, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
F381). Outcome was defined as 30-day mortality or approxi-
mated using hospital mortality, and as last resort ICU mortality 
if the former were unavailable (32). This study was performed 
in a dataset which was independent from a recent meta-analysis 
performed by our group (33).
Statistical Analysis
All quantitative variables were described using medians (quar-
tiles), whereas qualitative variables were described by frequen-
cies (percentage). Day 30 (D-30) mortality was the variable of 
primary interest. Raw change in mortality according to ICU 
admission year was assessed using Wilcoxon test. Change in 
mortality over time, weighted for number of observations 
per year, was plotted for the whole population and for pre-
defined subgroups using mean mortality for each admission 
year and change over time by linear regression with 95% CI. 
Independent predictors of mortality were assessed using 
logistic regression and mixed logistic models. Variables of in-
terest were selected according to their relevance and statistical 
significance in univariate analysis. We used conditional step-
wise regression with 0.2 as the critical p value for entry into 
the model, and 0.1 as the p value for removal. Variables with 
missing data rate above 10% were discarded from this analysis. 
The year of ICU admission was planned to be forced in the 
model in cases where the p value was greater than 0.2. Interac-
tions and correlations between the explanatory variables were 
carefully checked. Continuous variables for which log-linearity 
was not confirmed were transformed into categorical variables 
according to median or interquartile range (IQR). The final 
models were assessed by calibration, discrimination, and rele-
vance. Residuals were plotted and the distributions inspected. 
Then, mixed model was performed using variables previously 
selected as fixed effect. In order to investigate both study het-
erogeneity in the mortality rate and heterogeneity in the effect 
of the ICU admission year within studies, two random effects 
were introduced: respectively a random effect of study on the 
mean mortality rate (random intercept) and a random effect 
on the effect of the ICU admission year on within study mor-
tality (random slope) (34). This model adjusting for clustering 
effect was planned a priori to be main result of the analysis. 
Same validation methods were used as previously and cali-
bration was reported as calibration belt (35). Last sensitivity 
analysis in subgroup of patients with bacterial pneumonia as 
source of infection was performed following the same method. 
All tests were two-sided, and p values of less than 0.05 were 
considered statistically significant. Analyses were done using 
R software Version 3.4.4 (R Foundation for Statistical Com-
puting, Vienna, Austria; https://www.r-project.org), including 
lme4, lmerTest, and givitiR packages.
RESULTS
From 1994 to 2015, 4,636 critically ill cancer patients have been 
included in the GRRR-OH database, of which 2,062 patients 
with sepsis or septic shock (Supplemental Fig. 1, Supple-
mental Digital Content 2, http://links.lww.com/CCM/F382; 
legend, Supplemental Digital Content 7, http://links.lww.com/
CCM/F387). In this cohort, patients were predominantly male 
(n = 1,275 [61.8%]) and the median age was 59 years (48–67 yr) 
(Table 1). Underlying malignancies were solid tumors in 362 
patients (17.6%), mostly digestive tract cancers (n = 61; 16.9%) 
and breast cancers (n = 55; 15.2%) (Supplemental Table 2, 
Supplemental Digital Content 3, http://links.lww.com/CCM/
F383). Metastatic cancers in solid tumor population were pre-
sent in 174 patients (48.1%) and 211 patients (58.3%) received 
a systemic anti-cancer therapy within four weeks before ICU 
admission or during their ICU stay (Supplemental Table 2, 
Supplemental Digital Content 3, http://links.lww.com/CCM/
F383). Hematologic malignancies (n = 1,700 [82.4%]) included 
acute leukemia (n = 591; 28.7%), non-Hodgkin lymphoma 
(n = 461; 22.4%), and myeloma (n = 244; 11.8%). Two-hundred 
fifty patients (12.1%) underwent allogeneic hematopoietic stem 
cell transplantation (allo-HSCT) before ICU admission and 
640 (31.0%) were neutropenic at ICU admission. The median 
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(IQR) SOFA score at ICU admission was 6 (4–9) (Table 1). 
Data on D-30 mortality were available in 943 patients (45.7%), 
approximated using hospital mortality in 879 patients (42.6%) 
and as last resort ICU mortality if the former were unavailable. 
In this study, D-30 mortality rate was 39.9% (n = 823). By uni-
variate analysis, variables associated with D-30 mortality were 
the year of ICU admission, SOFA score at ICU admission, me-
chanical ventilation, noninvasive ventilation, vasopressors use, 
and renal replacement therapy (Table 1).
After adjustment for the SOFA score at ICU admission, the 
year of ICU admission was significantly associated with D-30 
mortality, decreasing over time (odds ratio [OR], 0.96; 95% CI, 
0.93–0.98; p = 0.001). D-30 mortality probability according to 
the year of ICU admission predicted by the mixed-effect model 
and adjusted for the SOFA score at ICU admission is presented in 
Figure 1. Furthermore, this significant decrease of mortality over 
time was found in the subgroup of patients with solid tumors 
(OR, –2.63; 95% CI, 0.86–0.98; p = 0.03) and in the subgroup 
of patients with hematologic malignancies (OR, –2.72; 95% CI, 
0.94–0.99; p < 0.01) (Fig. 2). Finally, a progressive decrease in 
mortality was observed in patients with (OR per year, 0.82; 95% 
CI, 0.82–0.95) and without (OR, 0.95; 95% CI, 0.92–0.98) mul-
tiple organ failure (Fig. 3). Numbers of withholding/withdrawing 
life-sustaining therapies did not evolve over time. After adjust-
ment for withholding/withdrawing life-sustaining therapies, the 
year of ICU admission was still significantly associated with D-30 
mortality (Supplemental Fig. 2, Supplemental Digital Content 4, 
http://links.lww.com/CCM/F384; legend, Supplemental Digital 
Content 7, http://links.lww.com/CCM/F387).
By multivariable logistic regression at ICU admission, me-
chanical ventilation (OR, 3.21; 95% CI, 2.50–4.13; p < 0.01) and 
vasopressors use (OR, 1.42; 95% CI, 1.10–1.83; p = 0.006) were 
risk factors for D-30 mortality. A hierarchical model taking into 
account the year of ICU admission and the source dataset as 
TABLE 1. Population Characteristics According to Day 30 Outcome
Variables
All  
(n = 2,062)
Survivors  
at Day 30  
(n = 1,205)
Nonsurvivors  
at Day 30  
(n = 823)
Univariate  
Analysis  
p
Gender, female, n (%) 787 (38.1) 465 (38.6) 322 (39.1) 1.00
Age, yr, median (IQR) 59 (48–67) 59 (47–67) 59 (49–68) 0.52
Year of inclusion, median (IQR) 2009 (2006–2010) 2010 (2007–2011) 2009 (2006–2010) < 0.01
Sequential Organ Failure Assessment score  
at ICU admission, median (IQR)
6 (4–9) 6 (4–9) 8 (5–11) < 0.01
Comorbidities, n (%) 1,043 (50.6) 645 (53.5) 398 (48.4) 0.41
Hematologic malignancies, n (%) 1,700 (82.4) 986 (81.8) 685 (83.2) 0.45
Allogeneic stem cell transplantation, n (%) 250 (12.1) 151 (12.5) 99 (12.0) 0.92
Neutropenia, n (%) 640 (31.0) 365 (30.3) 275 (33.4) 0.09
Acute respiratory failure, n (%) 927 (45.0) 578 (48.0) 349 (46.0) 0.50
Noninvasive ventilation, n (%) 635 (30.8) 357 (29.6) 278 (33.8) 0.05
Mechanical ventilation, n (%) 1,016 (49.3) 423 (35.1) 593 (72.0) < 0.01
Vasopressor use, n (%) 1,172 (56.8) 577 (47.9) 595 (72.3) < 0.01
Acute kidney injury, n (%) 291 (14.1) 173 (14.4) 118 (14.3) 0.31
Renal replacement therapy, n (%) 420 (20.4) 182 (15.1) 238 (28.9) < 0.01
IQR = interquartile range.
Figure 1. Thirty-day predicted mortality obtained by mixed-effect linear 
regression according to the year of ICU admission and adjusted on 
Sequential Organ Failure Assessment score at ICU admission.
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random variables was used to identify risk factors for D-30 mor-
tality. The calibration belt of the mixed-effect model is presented in 
Supplemental Figure 3 (Supplemental Digital Content 5, http://
links.lww.com/CCM/F385; legend, Supplemental Digital Content 
7, http://links.lww.com/CCM/F387). According to this model, me-
chanical ventilation (OR, 3.25; 95% CI, 2.52–4.19; p < 0.01) and 
vasopressors use (OR, 1.42; 95% CI, 1.10–1.83; p < 0.01) were sig-
nificantly associated with D-30 mortality (Fig. 4). Neutropenia and 
allo-HSCT were not significantly associated with D-30 mortality.
Based on the linear mixed-effect model, sensitivity analysis 
in the subgroup of patients with clinically or microbiologically 
documented bacterial pneumonia found similar results: ICU 
admission year (OR, 0.90; 95% CI, 0.90–0.91; p < 0.01), mechan-
ical ventilation (OR, 1.62; 95% CI, 1.06–2.50; p < 0.01), and renal 
replacement therapy (OR, 1.75; 95% CI, 1.14–2.70; p < 0.01) 
were significantly associated with D-30 mortality, whereas di-
sease characteristics or previous stem cell transplantation were 
not (Supplemental Fig. 4, Supplemental Digital Content 6, 
http://links.lww.com/CCM/F386; legend, Supplemental Digital 
Content 7, http://links.lww.com/CCM/F387).
DISCUSSION
This large multicenter study analyzing data from cancer 
patients admitted to the ICU for sepsis or septic shock put 
forward the continuing improved mortality in this high-risk 
patient population. To the best of our knowledge, this is the 
largest study assessing trends in survival rates over time in crit-
ically ill cancer patients with severe infections (11, 12).
With a D-30 mortality rate of 39.9%, this study suggests 
that mortality rates of cancer patients with sepsis is in line 
with those reported in patients with other severe comorbid 
conditions. Despite recent improvements and advances inpa-
tient’s management, mortality rates of sepsis in patients with 
malignancies remain higher than those in noncancer patients. 
However, earlier studies needed to be updated and the 60% 
mortality rate in cancer patients with severe sepsis and septic 
shock should be considered as not relevant anymore (10–12). 
Instead, cancer patients with severe infections exert survival 
rates that are in the ranges of those of patients with other severe 
comorbidities (9, 36, 37). Furthermore, in this study, almost a 
third of included patients had neutropenia secondary to recent 
Figure 2. Thirty-day mortality over the years according the type of tumor. Thirty-day predicted mortality obtained by mixed-effect linear regression 
according to the year of ICU admission and adjusted on Sequential Organ Failure Assessment score at ICU admission in (A) patients with solid tumors 
(B) patients with hematologic malignancies.
Figure 3. Thirty-day predicted mortality in patients with or without multiple 
organ failure obtained by mixed-effect linear regression according to the 
year of ICU admission. MOF = multiple organ failure.
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intensive treatments such as auto-HSCT or allo-HSCT or in-
tensive chemotherapy.
This study also generates hypotheses to explain why mor-
tality decreased in cancer patients with severe infection. A 
better selection of patients, the increased awareness of sepsis 
diagnosis and management optimization may have contrib-
uted to improve outcomes over time. Indeed, various adjuvant 
therapies for both septic shock and general ICU care have 
arisen to form the basis of recommendations of the differ-
ent Surviving Sepsis Campaigns (28, 38, 39). The compliance 
to the bundle of cares recommended by these international 
guidelines have been associated with increased survival of un-
selected ICU patients admitted for sepsis (37, 40). In critically 
ill cancer patients, Larché et al (41) followed by Pène et al (42) 
Figure 4. Risk factors for day 30 mortality determined by standard multivariate logistic regression and by mixed-effect linear regression at ICU 
admission. OR = odds ratio, RRT = renal replacement therapy.
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also showed an improved outcome over time in patients with 
septic shock by comparing the mortality rates between two 
different time periods. Specific cares related to immunocom-
promised patients have also been developed in the past years, 
potentially explaining the decreased mortality in this popula-
tion over time. For instance, Azoulay et al (21) reported that 
noninvasive diagnostic strategy for acute respiratory failure 
etiology was not inferior to invasive testing. Different venti-
lation strategies have also been specifically tested (19, 43). 
Furthermore, a better collaboration between oncologists/
hematologists and intensive care doctors has dramatically 
improved the outcomes of patients with malignancies admitted 
to the ICU (5). In the ORCHESTRA study, Soares et al (5, 44) 
retrospectively reviewed onco-hematologic patients hospital-
ized in 51 ICUs from general hospitals and in 19 ICUs from 
cancer centers in Brazil. The authors found that presence of 
clinical pharmacists in the ICU, presence of ICU protocols, and 
daily meetings between oncologists and intensivists were asso-
ciated with lower hospital mortality even after adjustment for 
hospital case volume. Finally, triage policies for ICU admission 
have evolved over time in cancer patients. Indeed, ICU triage 
criteria that are usually used are unreliable. An international 
expert consensus has issued ICU admission recommendations 
for critically ill patients with cancer (45). Different therapeutic 
strategies may be considered according to the patient and his 
disease; from full code management to 3 days ICU “trial” or 
no ICU admission/no intensified intensive care treatment. 
Furthermore, early ICU admission in case of acute physiologic 
disturbances or minor organ impairment in this specific pop-
ulation has been associated with improved survival, specifi-
cally in case of sepsis (20, 46–50). Thus, early ICU admission 
explains why almost half of the patients of our cohort admit-
ted in ICU for sepsis had no need for vasopressor support. 
Interestingly, in the present study, allo-HSCT was not associ-
ated with D-30 mortality. Major advances have been made in 
the care of patients undergoing allo-HSCT over the last decade 
resulting in improved outcome (51, 52). ICU admission of 
allo-HSCT patients has been controversial. Studies from 1990s 
reported mortality rates over 90% (53). However, decrease in 
overall mortality, nonrelapse mortality, severe graft-versus-
host disease, infections, and liver, kidney, and lung damages 
have been reported (54, 55). In a recent meta-analysis including 
2,342 patients, ICU mortality rate was 51.7%. Furthermore, 
survival of critically ill adult allo-HSCT patients admitted to 
the ICU increased over time, supporting the usefulness of ICU 
management in well-selected patients (56). Thus, early admis-
sion of patients with only one organ failure can be beneficial 
in the allo-HSCT population, whereas attempt to resuscitate 
multiple organ failure mostly fails (3, 57).
According to these findings, neutropenia was not associated 
with D-30 mortality. Neutropenia is associated with complica-
tions like severe sepsis (20) or acute respiratory failure (58). 
Although these side effects are likely to influence the outcome 
of critically ill patients, several recent studies failed to dem-
onstrate an impact of neutropenia on the outcome of criti-
cally ill patients (13) and showed a meaningful survival in this 
subgroup of patients (59). Conversely, a recent meta-analysis 
showed that neutropenia was independently associated with 
poor outcome in ICU patients (60). However, all these studies 
did not specifically address the issue of discrepancies in ad-
mission policies across studies, which might explain reported 
differences.
Last, we report in this analysis that the presence of organ 
failures remained the main determinant of outcome in criti-
cally ill cancer patients. In patients with solid tumor, Vincent 
et al (61) suggested that risk factors for 120 days mortality after 
ICU were the type of cancer, systemic extension of the disease, 
need for invasive mechanical ventilation, vasopressors, or 
renal replacement therapy. Furthermore, in a recent published 
study, de Vries et al (62) showed that 1-year mortality rate of 
patients with hematologic malignancies increased with the 
number of organ failure, with a survival rate among patients 
with two, three, and four failing organs of 27%, 22%, and 8%, 
respectively.
This study has several limitations. First, data on cancer 
patients admitted in seven participating ICUs and included 
in 14 different studies over a time period of 21 years were 
extracted from the GRRR-OH database and analyzed. Thus, 
these patients are representative of selected studies popula-
tions, which could limit generalizability of the data. This bias 
of selection may also explain the difference in numbers of 
patients with hematologic malignancies and those with solid 
tumors. Second, some data on patients with solid tumors are 
lacking, especially on the primary site of cancer and the met-
astatic status of the disease, restricting the external validity of 
the data on solid cancer patients. Furthermore, the date of the 
last inclusion was January 2015. Therefore, patients received 
chemotherapy regimens but none of them were treated by 
immunotherapy nor cancer targeted treatments. We ac-
knowledge that these new treatments may have changed the 
prognosis of critically ill onco-hematologic patients (63). The 
study design does not allow us to ascribe reported survival 
benefits to specific targets. However, it is likely that more 
than single interventions, a global and comprehensive man-
agement has actually improved outcomes. Furthermore, anti-
infectious agents have not been assessed in detail so that we 
are not in capacity to tackle the issue of appropriate antibi-
otics and source control, two tenets in the management of 
sepsis. The present study includes only patients who were 
considered eligible for ICU admission. This may have intro-
duced a selection bias due to the triage process performed 
before ICU admission. Finally, as the data collection was ret-
rospective for some studies, potential confounding factors 
may have been overlooked.
CONCLUSIONS
Survival in critically ill oncology and hematology patients with 
sepsis improved significantly over time. Given the high fre-
quency of malignancy among patients with septic shock, stud-
ies are needed to identify targets to further improve survival in 
this growing subgroup of ICU patients.
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